7OC0 Stock Chart & Stats
€3.28
-€0.10(-2.43%)
At close: 4:00 PM EDT
€3.28
-€0.10(-2.43%)
Day’s Range― - ―
52-Week Range€2.40 - €7.35
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€87.88M
Enterprise Value€200.97M
Total Cash (Recent Filing)€17.76M
Total Debt (Recent Filing)€2.63M
Price to Earnings (P/E)―
Beta0.92
Next Earnings
Nov 05, 2026EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.52
Shares Outstanding32,724,285
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)-7.26
Price to Sales (P/S)56.37
P/FCF Ratio-9.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€8.61Price Target Upside162.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.81
Revenue Forecast (FY)€865.00K
Bulls Say, Bears Say
Bulls Say
Expanded Reimbursement OpportunityBroader Medicare-backed testing frequency improves the economic case for the company’s kitted transplant assays and expands potential utilization. This structural reimbursement change can support market growth, customer adoption, and recurring testing demand beyond the current development stage.
Clinical Validation And Customer ReachReportedly strong comparative data and engagement from leading transplant centers strengthen the company’s credibility with laboratories and clinicians. This evidence can reduce adoption friction and support a durable commercial position if regulatory and reimbursement milestones are achieved.
Product Roadmap And Market PotentialA sizable stated addressable market, higher surveillance frequency, therapy monitoring, and expansion into other organs provide multiple avenues for future growth. The claimed development lead could further improve competitive positioning as the company approaches commercialization.
Bears Say
Small And Declining Revenue BaseThe company remains at an early commercial scale, with modest revenue, declining sales, and low gross margin relative to its operating needs. This limits internal funding capacity and means future financial performance remains highly dependent on successful product adoption and revenue ramp-up.
Sustained Cash BurnDeeply negative operating and free cash flow show that the current business model is consuming substantial cash before meaningful revenue scale has been established. Continued investment in regulatory, registry, and launch activities increases dependence on external capital or a rapid improvement in sales.
Negative Stockholders’ EquityNegative equity reflects cumulative losses and weakens the company’s financial flexibility even though total debt is relatively small. It can make future financing more difficult and leaves less balance-sheet capacity to absorb delays, continued losses, or slower-than-expected commercialization.
Insight Molecular Diagnostics News
7OC0 FAQ
What was Insight Molecular Diagnostics’s price range in the past 12 months?
Insight Molecular Diagnostics lowest stock price was €2.40 and its highest was €7.35 in the past 12 months.
What is Insight Molecular Diagnostics’s market cap?
Insight Molecular Diagnostics’s market cap is €87.88M.
When is Insight Molecular Diagnostics’s upcoming earnings report date?
Insight Molecular Diagnostics’s upcoming earnings report date is Nov 05, 2026 which is in 9 days.
How were Insight Molecular Diagnostics’s earnings last quarter?
Insight Molecular Diagnostics released its earnings results on Aug 10, 2026. The company reported -€0.277 earnings per share for the quarter, missing the consensus estimate of -€0.227 by -€0.05.
Is Insight Molecular Diagnostics overvalued?
According to Wall Street analysts Insight Molecular Diagnostics’s price is currently Undervalued.
Does Insight Molecular Diagnostics pay dividends?
Insight Molecular Diagnostics does not currently pay dividends.
What is Insight Molecular Diagnostics’s EPS estimate?
Insight Molecular Diagnostics’s EPS estimate is -0.21.
How many shares outstanding does Insight Molecular Diagnostics have?
Insight Molecular Diagnostics has 32,724,285 shares outstanding.
What happened to Insight Molecular Diagnostics’s price movement after its last earnings report?
Insight Molecular Diagnostics reported an EPS of -€0.277 in its last earnings report, missing expectations of -€0.227. Following the earnings report the stock price went down -5.392%.
Which hedge fund is a major shareholder of Insight Molecular Diagnostics?
Currently, no hedge funds are holding shares in DE:7OC0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Insight Molecular Diagnostics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€8.61 (162.62% Upside)
€8.61 (162.62% Upside)
Blogger Sentiment
Bearish
DE:7OC0 Sentiment 100%
Sector Average 67%
Sector Average 67%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-54.75%
12-Months-Change
Fundamentals
Return on Equity
271.76%
Trailing 12-Months
Asset Growth
-41.72%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Insight Molecular Diagnostics
OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis. Additionally, OncoCyte provides a range of expert services, such as biomarker discovery, assay design and refinement, and clinical trial assistance, which encompass offering various biomarker tests to pharmaceutical partners. A strategic partnership with Life Technologies Corporation focuses on the collaborative development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, intended for integration with the Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was founded in 2009 and maintains its principal office in Irvine, California.
7OC0 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveys a generally positive operational and commercial outlook driven by regulatory progress (SIR meeting and tripled study samples), favorable Medicare coverage expansion (+75% surveillance tests in first 3 years), strong head-to-head clinical data and customer engagement (over half of top-10 transplant centers engaged), and a clear TAM expansion pathway. Offsetting these positives are material near-term financial risks — elevated cash burn ($10M in Q2; expected ~$8M/quarter in H2, up ~33% vs prior guidance), ongoing adjusted EBITDA losses ($7.8M) and schedule uncertainty around FDA authorization that could delay commercialization. Overall, management’s tone is constructive and forward-looking, but execution and timing risks remain important near-term considerations.View all DE:7OC0 earnings summaries7OC0 Stock 12 Month Forecast
Average Price Target
€8.61
▲(162.62% Upside)
Technical Analysis
Atossa Therapeutics
―
MacroGenics
―
Elutia
―
Surrozen
―
Telomir Pharmaceuticals, Inc.
―